Challenges of advanced hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause of death by cancer each year. The management of patients with HCC is complex, as both the tumour stage and any underlying liver disease must be considered conjointly. Although surveillance by imaging, clinical and biochemical parameters is routinely performed, a lot of patients suffering from cirrhosis have an advanced stage HCC at the first diagnosis. Advanced stage HCC includes heterogeneous groups of patients with different clinical condition and radiological features and sorafenib is the only approved treatment according to Barcelona Clinic Liver Cancer. Since the introduction of sorafenib in clinical practice, several phase III clinical trials have failed to demonstrate any superiority over sorafenib in the frontline setting. Loco-regional therapies have also been tested as first line treatment, but their role in advanced HCC is still matter of debate. No single agent or combination therapies have been shown to impact outcomes after sorafenib failure. Therefore this review will focus on the range of experimental therapeutics for patients with advanced HCC and highlights the successes and failures of these treatments as well as areas for future development. Specifics such as dose limiting toxicity and safety profile in patients with liver dysfunction related to the underlying chronic liver disease should be considered when developing therapies in HCC. Finally, robust validated and reproducible surrogate end-points as well as predictive biomarkers should be defined in future randomized trials.
Stefano Colagrande, Gian Giacomo Taliani, Cosimo Nardi, Dipartimento di Scienze Biomediche Sperimentali e Cliniche, University of Florence, I-50134 Florence, Italy.
Stefano
S
Colagrande
Stefano Colagrande, Gian Giacomo Taliani, Cosimo Nardi, Dipartimento di Scienze Biomediche Sperimentali e Cliniche, University of Florence, I-50134 Florence, Italy.
Andrea L
AL
Inghilesi
Stefano Colagrande, Gian Giacomo Taliani, Cosimo Nardi, Dipartimento di Scienze Biomediche Sperimentali e Cliniche, University of Florence, I-50134 Florence, Italy.
Sami
S
Aburas
Stefano Colagrande, Gian Giacomo Taliani, Cosimo Nardi, Dipartimento di Scienze Biomediche Sperimentali e Cliniche, University of Florence, I-50134 Florence, Italy.
Gian G
GG
Taliani
Stefano Colagrande, Gian Giacomo Taliani, Cosimo Nardi, Dipartimento di Scienze Biomediche Sperimentali e Cliniche, University of Florence, I-50134 Florence, Italy.
Cosimo
C
Nardi
Stefano Colagrande, Gian Giacomo Taliani, Cosimo Nardi, Dipartimento di Scienze Biomediche Sperimentali e Cliniche, University of Florence, I-50134 Florence, Italy.
Fabio
F
Marra
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D008099:Liver / Q000503:physiopathology; D008113:Liver Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D010671:Phenylurea Compounds / Q000008:administration & dosage; D011169:Portal Vein / Q000473:pathology; D000077157:Sorafenib; D013927:Thrombosis
D014408:Biomarkers, Tumor; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib
Advanced hepatocellular carcinoma management; Advanced hepatocellular carcinoma second line therapies; Barcelona Clinic Liver Cancer; Modified Response Evaluation Criteria in Solid Tumors; Portal vein thrombosis; Sorafenib
Hepatology. 2008 Jan;47(1):71-81
18027884
Gut. 2014 May;63(5):844-55
24531850
J Clin Oncol. 2013 Oct 1;31(28):3509-16
23980090
Hepatology. 2011 Sep 2;54(3):868-78
21618574
Medicine (Baltimore). 2015 Apr;94(14):e688
25860213
Cancer Res. 2004 Oct 1;64(19):7099-109
15466206
JAMA. 2010 Nov 17;304(19):2154-60
21081728
Aliment Pharmacol Ther. 2014 Aug;40(3):221-32
24942957
Cancer Nurs. 2009 Sep-Oct;32(5):398-403
19661795
Cochrane Database Syst Rev. 2004;(3):CD003445
15266485
Lancet. 2012 Mar 31;379(9822):1245-55
22353262
Aliment Pharmacol Ther. 2013 Jun;37(12 ):1132-56
23638982
Radiology. 2010 Jan;254(1):47-66
20032142
Dig Liver Dis. 2013 Sep;45(9):776-81
23578581
World J Hepatol. 2012 Sep 27;4(9):256-61
23060970
Cardiovasc Intervent Radiol. 2011 Apr;34(2):306-18
20683722
Gut Liver. 2013 Nov;7(6):696-703
24312711
J Clin Oncol. 2015 Feb 20;33(6):559-66
25547503
J Hepatol. 2014 Apr;60(4):732-40
24308991
Gastroenterology. 2011 Feb;140(2):497-507.e2
21044630
AJR Am J Roentgenol. 2007 Mar;188(3):768-75
17312067
Oncology. 2007;72(5-6):285-92
18187950
Oncologist. 2008 Feb;13(2):120-5
18305056
Palliat Med. 2004 Mar;18(2):93-9
15046405
Ann Surg Oncol. 2006 Jul;13(7):940-6
16788755
BMC Gastroenterol. 2014 May 03;14:84
24886354
Oncologist. 2010;15(1):85-92
20051477
J Hepatol. 2016 May;64(5):1090-8
26809111
Crit Rev Oncol Hematol. 2014 Jul;91(1):1-8
24457121
Int J Cancer. 2006 Jun 15;118(12):3030-44
16404738
Gut. 2001 Jan;48(1):103-9
11115830
J Clin Oncol. 2013 Nov 10;31(32):4067-75
24081937
Semin Liver Dis. 2010 Feb;30(1):52-60
20175033
Liver Int. 2013 Jul;33(6):950-7
23601249
Am J Clin Oncol. 2013 Aug;36(4):319-24
22547010
JAMA. 2014 Jul 2;312(1):57-67
25058218
BMC Cancer. 2009 Jun 28;9:208
19558720
Lancet Oncol. 2015 Jul;16(7):859-70
26095784
BMC Gastroenterol. 2013 Jan 22;13:18
23339829
Eur J Cancer. 2011 Sep;47(14):2117-27
21664811
PLoS One. 2014 Jul 24;9(7):e102761
25058587
Eur J Cancer. 2015 Feb;51(3):327-39
25559615
Future Oncol. 2014 Oct;10(13):2073-9
25396778
BMC Gastroenterol. 2013 Apr 08;13:60
23566041
J Vasc Interv Radiol. 2010 Aug;21(8):1205-12
20598574
Radiology. 2008 Jun;247(3):726-32
18403621
Oncologist. 2009 Jul;14(7):717-25
19581525
Nutr Res. 2009 Feb;29(2):89-93
19285598
Oncology. 2013;84(1):6-13
23075905
Abdom Imaging. 2009 Sep-Oct;34(5):566-81
18777189
Liver Int. 2015 Mar;35(3):1036-47
24750853
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
J Clin Oncol. 2013 Oct 1;31(28):3517-24
23980084
Radiology. 2011 Feb;258(2):627-34
21273524
Invest Radiol. 2006 Oct;41(10 ):753-62
16971799
Radiology. 2016 May;279(2):630-40
26744927
Aliment Pharmacol Ther. 2006 Jun 1;23(11):1535-47
16696801
Clin Oncol (R Coll Radiol). 2014 Aug;26(8):488-96
24856442
J Gastroenterol. 2014 Dec;49(12):1578-87
24499826
Clin Pharmacol Ther. 1988 Sep;44(3):353-9
3262026
Radiology. 2007 Jun;243(3):736-43
17517931
Nutr Cancer. 2014;66(3):517-22
24033366
J Hepatol. 2014 Aug;61(2):318-24
24703956
World J Surg. 2013 Jun;37(6):1362-70
23456227
Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74
17160391
Aliment Pharmacol Ther. 2004 Apr 1;19(7):779-88
15043519
Hepatology. 2016 Aug;64(2):695-6
26175073
Am J Clin Oncol. 1982 Dec;5(6):649-55
7165009
Liver Int. 2015 Feb;35(2):620-6
24930619
Mol Cancer Ther. 2008 Oct;7(10 ):3129-40
18852116
Oncology. 2012;83(4):192-200
22890083
J Hepatol. 2013 Jun;58(6):1181-7
23395691
Lancet Oncol. 2009 Jan;10(1):25-34
19095497
J Hepatol. 2012 Jul;57(1):101-7
22414760
Hepatology. 2015 Oct;62(4):1111-21
25999236
Br J Surg. 1973 Aug;60(8):646-9
4541913
J Egypt Natl Canc Inst. 2013 Dec;25(4):165-71
24207088
Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):244-50
16235981
Clin Gastroenterol Hepatol. 2014 Apr;12(4):692-8
23978345
Hepatology. 2011 Dec;54(6):2055-63
21898496
Am J Prev Med. 2012 Aug;43(2):e1-24
22813691
Oncologist. 2014 Apr;19(4):394-402
24652387
Support Care Cancer. 2014 Apr;22(4):919-26
24258355
Nutr J. 2015 Jul 09;14:67
26155840
Int J Clin Pharmacol Ther. 2013 Nov;51(11):837-46
24075093
Cancer Nurs. 2011 Sep-Oct;34(5):354-60
21242769
J Hepatol. 2010 Jul;53(1):126-31
20416968
Radiographics. 2013 Sep-Oct;33(5):1323-41
24025927
Clin Gastroenterol Hepatol. 2010 Jul;8(7):559-64.e1-10
20304101
J Hepatol. 2013 Mar;58(3):509-21
23178978
J Gastroenterol Hepatol. 2010 Nov;25(11):1739-46
21039835
Oncologist. 2008;13 Suppl 2:4-7
18434631
Hepatology. 2010 Apr;51(4):1274-83
20112254
Br J Cancer. 2010 Mar 16;102(6):981-6
20160718
Hepatology. 2008 Oct;48(4):1312-27
18821591
Gastroenterology. 2010 Jan;138(1):52-64
19766639
Cochrane Database Syst Rev. 2012 May 16;(5):CD008344
22592729
J Clin Gastroenterol. 2013 Apr;47(4):359-66
23090049
AJR Am J Roentgenol. 2014 Jul;203(1):W78-84
24951231
Nat Genet. 2015 May;47(5):505-11
25822088
J Clin Oncol. 2015 Jan 10;33(2):172-9
25488963
Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):635-43
26455499
Oncol Lett. 2013 Dec;6(6):1707-1712
24260066
J Clin Oncol. 2013 Nov 1;31(31):3980-6
24062394
Am J Clin Pathol. 2008 Feb;129(2):245-51
18208805
Liver Cancer. 2015 Dec;4(4):201-7
26732472
Br J Cancer. 2011 Sep 27;105(7):945-52
21863030
Hepatology. 2014 Feb;59(2):705-12
23744627
Oncology. 2014;86(4):191-8
24800837
Am J Gastroenterol. 2007 Apr;102(4):744-53
17222324
Cancer. 2010 Jul 15;116(14):3513-20
20564068
Cancer. 2012 Jan 1;118(1):147-56
21713764
Eur J Gastroenterol Hepatol. 2015 Jul;27(7):853-9
25919775
J Clin Oncol. 2013 Oct 1;31(28):3501-8
23980077
Semin Liver Dis. 2013 Feb;33 Suppl 1:S20-3
23457036
J Vasc Interv Radiol. 2004 Apr;15(4):335-45
15064336
Eur J Clin Pharmacol. 1991;41(4):351-4
1839532
Hepatology. 2013 Dec;58(6):2023-31
23787822
Clin Cancer Res. 2012 Apr 15;18(8):2290-300
22374331
Clin Mol Hepatol. 2015 Dec;21(4):344-8
26770921